Annual CFF
-$5.13 M
-$7.56 M-310.85%
December 31, 2023
Summary
- As of February 7, 2025, AUPH annual cash flow from financing activities is -$5.13 million, with the most recent change of -$7.56 million (-310.85%) on December 31, 2023.
- During the last 3 years, AUPH annual CFF has fallen by -$199.50 million (-102.64%).
- AUPH annual CFF is now -102.10% below its all-time high of $243.85 million, reached on December 31, 2019.
Performance
AUPH Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$2.72 M
+$5.55 M+67.10%
September 30, 2024
Summary
- As of February 7, 2025, AUPH quarterly cash flow from financing activities is -$2.72 million, with the most recent change of +$5.55 million (+67.10%) on September 30, 2024.
- Over the past year, AUPH quarterly CFF has increased by +$5.55 million (+67.10%).
- AUPH quarterly CFF is now -101.32% below its all-time high of $205.72 million, reached on December 31, 2021.
Performance
AUPH Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$31.62 M
-$390.00 K-1.25%
September 30, 2024
Summary
- As of February 7, 2025, AUPH TTM cash flow from financing activities is -$31.62 million, with the most recent change of -$390.00 thousand (-1.25%) on September 30, 2024.
- Over the past year, AUPH TTM CFF has dropped by -$390.00 thousand (-1.25%).
- AUPH TTM CFF is now -108.11% below its all-time high of $390.05 million, reached on September 30, 2020.
Performance
AUPH TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AUPH Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -310.9% | +67.1% | -1.3% |
| 3 y3 years | -102.6% | -100.0% | -115.2% |
| 5 y5 years | -227.8% | -100.0% | -115.2% |
AUPH Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -102.3% | at low | -101.3% | +81.9% | -114.3% | at low |
| 5 y | 5-year | -102.1% | at low | -101.3% | +81.9% | -108.1% | at low |
| alltime | all time | -102.1% | +46.6% | -101.3% | +81.9% | -108.1% | at low |
Aurinia Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.72 M(-67.1%) | -$31.62 M(+1.2%) |
| Jun 2024 | - | -$8.27 M(-45.0%) | -$31.23 M(+43.1%) |
| Mar 2024 | - | -$15.05 M(+169.9%) | -$21.82 M(+325.3%) |
| Dec 2023 | -$5.13 M(-310.9%) | -$5.58 M(+139.2%) | -$5.13 M(-552.0%) |
| Sep 2023 | - | -$2.33 M(-304.6%) | $1.14 M(-67.3%) |
| Jun 2023 | - | $1.14 M(-30.4%) | $3.47 M(-5.5%) |
| Mar 2023 | - | $1.64 M(+138.2%) | $3.67 M(+50.7%) |
| Dec 2022 | $2.43 M(-98.9%) | $688.00 K(>+9900.0%) | $2.43 M(-98.8%) |
| Sep 2022 | - | $0.00(-100.0%) | $207.47 M(-4.2%) |
| Jun 2022 | - | $1.34 M(+230.9%) | $216.55 M(+0.0%) |
| Mar 2022 | - | $405.00 K(-99.8%) | $216.49 M(-2.1%) |
| Dec 2021 | $221.11 M(+13.8%) | $205.72 M(+2165.2%) | $221.11 M(+1229.4%) |
| Sep 2021 | - | $9.08 M(+610.1%) | $16.63 M(-91.5%) |
| Jun 2021 | - | $1.28 M(-74.6%) | $196.81 M(+0.2%) |
| Mar 2021 | - | $5.03 M(+304.9%) | $196.48 M(+1.1%) |
| Dec 2020 | $194.38 M(-20.3%) | $1.24 M(-99.3%) | $194.38 M(-50.2%) |
| Sep 2020 | - | $189.26 M(>+9900.0%) | $390.05 M(+80.9%) |
| Jun 2020 | - | $954.00 K(-67.4%) | $215.64 M(+0.2%) |
| Mar 2020 | - | $2.92 M(-98.5%) | $215.13 M(-11.8%) |
| Dec 2019 | $243.85 M(+5975.1%) | $196.92 M(+1226.0%) | $243.85 M(+412.8%) |
| Sep 2019 | - | $14.85 M(+3314.0%) | $47.55 M(+45.4%) |
| Jun 2019 | - | $435.00 K(-98.6%) | $32.71 M(-8.3%) |
| Mar 2019 | - | $31.65 M(+5071.7%) | $35.66 M(+788.5%) |
| Dec 2018 | $4.01 M(-97.7%) | $612.00 K(+7550.0%) | $4.01 M(+16.1%) |
| Sep 2018 | - | $8000.00(-99.8%) | $3.46 M(-26.3%) |
| Jun 2018 | - | $3.39 M(>+9900.0%) | $4.69 M(+57.9%) |
| Mar 2018 | - | $0.00(-100.0%) | $2.97 M(-98.3%) |
| Dec 2017 | $175.15 M(+311.0%) | $55.00 K(-95.6%) | $175.15 M(-14.0%) |
| Sep 2017 | - | $1.24 M(-25.7%) | $203.64 M(-3.0%) |
| Jun 2017 | - | $1.67 M(-99.0%) | $209.83 M(-2.3%) |
| Mar 2017 | - | $172.18 M(+503.3%) | $214.79 M(+404.0%) |
| Dec 2016 | $42.62 M(+4979.3%) | $28.54 M(+283.9%) | $42.62 M(+202.8%) |
| Sep 2016 | - | $7.43 M(+12.0%) | $14.07 M(+110.2%) |
| Jun 2016 | - | $6.64 M(>+9900.0%) | $6.70 M(+1324.7%) |
| Mar 2016 | - | $0.00(0.0%) | $470.00 K(-44.0%) |
| Dec 2015 | $839.00 K(-98.2%) | $0.00(-100.0%) | $839.00 K(-39.2%) |
| Sep 2015 | - | $56.00 K(-86.5%) | $1.38 M(-23.4%) |
| Jun 2015 | - | $414.00 K(+12.2%) | $1.80 M(+26.7%) |
| Mar 2015 | - | $369.00 K(-31.9%) | $1.42 M(-97.0%) |
| Dec 2014 | $47.89 M(+651.2%) | $542.00 K(+13.6%) | $47.89 M(+1.2%) |
| Sep 2014 | - | $477.00 K(+1302.9%) | $47.34 M(-9.6%) |
| Jun 2014 | - | $34.00 K(-99.9%) | $52.39 M(-1.6%) |
| Mar 2014 | - | $46.84 M(<-9900.0%) | $53.22 M(+734.8%) |
| Dec 2013 | $6.38 M(+789.5%) | -$6000.00(-100.1%) | $6.38 M(-10.6%) |
| Sep 2013 | - | $5.53 M(+541.2%) | $7.13 M(+347.9%) |
| Jun 2013 | - | $862.00 K(<-9900.0%) | $1.59 M(+121.2%) |
| Mar 2013 | - | -$8000.00(-101.1%) | $719.70 K(+0.4%) |
| Dec 2012 | $716.70 K(-68.6%) | $750.20 K(-6404.2%) | $716.70 K(-8734.9%) |
| Sep 2012 | - | -$11.90 K(+12.3%) | -$8300.00(-94.7%) |
| Jun 2012 | - | -$10.60 K(-3.6%) | -$157.60 K(+13.7%) |
| Mar 2012 | - | -$11.00 K(-143.7%) | -$138.60 K(-106.1%) |
| Dec 2011 | $2.28 M | $25.20 K(-115.6%) | $2.28 M(-1.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2011 | - | -$161.20 K(-2019.0%) | $2.32 M(-67.0%) |
| Jun 2011 | - | $8400.00(-99.7%) | $7.05 M(-0.1%) |
| Mar 2011 | - | $2.41 M(+3507.3%) | $7.05 M(+51.9%) |
| Dec 2010 | $4.64 M(-148.3%) | $66.80 K(-98.5%) | $4.64 M(+6.0%) |
| Sep 2010 | - | $4.56 M(>+9900.0%) | $4.38 M(-568.9%) |
| Jun 2010 | - | $16.10 K(>+9900.0%) | -$934.20 K(+3808.8%) |
| Mar 2010 | - | $0.00(-100.0%) | -$23.90 K(-99.8%) |
| Dec 2009 | -$9.61 M(-193.1%) | -$196.00 K(-74.0%) | -$9.61 M(-12.3%) |
| Sep 2009 | - | -$754.30 K(-181.4%) | -$10.96 M(+1.1%) |
| Jun 2009 | - | $926.40 K(-109.7%) | -$10.84 M(-1121.9%) |
| Mar 2009 | - | -$9.59 M(+520.7%) | $1.06 M(-89.7%) |
| Dec 2008 | $10.32 M(-71.4%) | -$1.54 M(+142.5%) | $10.32 M(-10.4%) |
| Sep 2008 | - | -$636.90 K(-105.0%) | $11.52 M(-18.8%) |
| Jun 2008 | - | $12.83 M(-4041.6%) | $14.19 M(+288.9%) |
| Mar 2008 | - | -$325.50 K(-5.2%) | $3.65 M(-89.9%) |
| Dec 2007 | $36.03 M(-2932.0%) | -$343.40 K(-117.0%) | $36.03 M(-0.0%) |
| Sep 2007 | - | $2.02 M(-11.7%) | $36.04 M(+7.2%) |
| Jun 2007 | - | $2.29 M(-92.9%) | $33.60 M(+8.6%) |
| Mar 2007 | - | $32.06 M(-9681.2%) | $30.94 M(-2531.9%) |
| Dec 2006 | -$1.27 M(-108.3%) | -$334.60 K(-18.7%) | -$1.27 M(+62.2%) |
| Sep 2006 | - | -$411.70 K(+10.1%) | -$784.40 K(-105.2%) |
| Jun 2006 | - | -$374.10 K(+146.4%) | $15.10 M(-2.3%) |
| Mar 2006 | - | -$151.80 K(-199.1%) | $15.46 M(+1.3%) |
| Dec 2005 | $15.26 M(+213.7%) | $153.20 K(-99.0%) | $15.26 M(-4.6%) |
| Sep 2005 | - | $15.47 M(<-9900.0%) | $16.00 M(+252.1%) |
| Jun 2005 | - | -$12.80 K(-96.3%) | $4.55 M(+0.6%) |
| Mar 2005 | - | -$348.00 K(-138.8%) | $4.52 M(-7.1%) |
| Dec 2004 | $4.87 M(-80.2%) | $896.20 K(-77.6%) | $4.87 M(+9.7%) |
| Sep 2004 | - | $4.01 M(<-9900.0%) | $4.43 M(-69.9%) |
| Jun 2004 | - | -$39.00 K(+2500.0%) | $14.72 M(-40.9%) |
| Mar 2004 | - | -$1500.00(-100.3%) | $24.90 M(+1.1%) |
| Dec 2003 | $24.62 M(+103.5%) | $465.10 K(-96.7%) | $24.62 M(+2.7%) |
| Sep 2003 | - | $14.30 M(+41.1%) | $23.97 M(+164.3%) |
| Jun 2003 | - | $10.13 M(-3719.5%) | $9.07 M(+6.0%) |
| Mar 2003 | - | -$280.00 K(+57.0%) | $8.56 M(-29.2%) |
| Dec 2002 | $12.10 M(-60.2%) | -$178.30 K(-70.5%) | $12.10 M(-1.5%) |
| Sep 2002 | - | -$604.60 K(-106.3%) | $12.27 M(-61.2%) |
| Jun 2002 | - | $9.62 M(+195.5%) | $31.61 M(+33.0%) |
| Mar 2002 | - | $3.26 M(-82.6%) | $23.76 M(-5.4%) |
| Dec 2001 | $30.41 M(+91.4%) | - | - |
| Aug 2001 | - | $18.73 M(+956.9%) | $25.13 M(+232.8%) |
| May 2001 | - | $1.77 M(+154.1%) | $7.55 M(-49.7%) |
| Feb 2001 | - | $697.70 K(-82.2%) | $15.00 M(-5.6%) |
| Nov 2000 | $15.89 M(+277.4%) | $3.92 M(+238.1%) | $15.89 M(+5.6%) |
| Aug 2000 | - | $1.16 M(-87.4%) | $15.04 M(+12.9%) |
| May 2000 | - | $9.23 M(+482.1%) | $13.33 M(+193.8%) |
| Feb 2000 | - | $1.58 M(-48.4%) | $4.54 M(+7.7%) |
| Nov 1999 | $4.21 M(+169.5%) | $3.07 M(-650.7%) | $4.21 M(+270.1%) |
| Aug 1999 | - | -$558.00 K(-228.0%) | $1.14 M(-32.9%) |
| May 1999 | - | $436.00 K(-65.4%) | $1.70 M(+34.6%) |
| Feb 1999 | - | $1.26 M | $1.26 M |
| Nov 1998 | $1.56 M | - | - |
FAQ
- What is Aurinia Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Aurinia Pharmaceuticals?
- What is Aurinia Pharmaceuticals annual CFF year-on-year change?
- What is Aurinia Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Aurinia Pharmaceuticals?
- What is Aurinia Pharmaceuticals quarterly CFF year-on-year change?
- What is Aurinia Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Aurinia Pharmaceuticals?
- What is Aurinia Pharmaceuticals TTM CFF year-on-year change?
What is Aurinia Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of AUPH is -$5.13 M
What is the all time high annual CFF for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals all-time high annual cash flow from financing activities is $243.85 M
What is Aurinia Pharmaceuticals annual CFF year-on-year change?
Over the past year, AUPH annual cash flow from financing activities has changed by -$7.56 M (-310.85%)
What is Aurinia Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of AUPH is -$2.72 M
What is the all time high quarterly CFF for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals all-time high quarterly cash flow from financing activities is $205.72 M
What is Aurinia Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, AUPH quarterly cash flow from financing activities has changed by +$5.55 M (+67.10%)
What is Aurinia Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of AUPH is -$31.62 M
What is the all time high TTM CFF for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals all-time high TTM cash flow from financing activities is $390.05 M
What is Aurinia Pharmaceuticals TTM CFF year-on-year change?
Over the past year, AUPH TTM cash flow from financing activities has changed by -$390.00 K (-1.25%)